February 10, 2015

To: EP02003.021 Registry owners/IRBs

RE: Finasteride Nordic Registry Study (EP02003.021) - Administrative Change Letter

---

This memo serves to notify registry owners that the timelines for the Finasteride Nordic Registry Study have been adjusted. In addition, after discussion with experts and after ensuring available specifications/coding of the variables from the different country registries, the tables on potential confounding factors, factors potentially associated with surveillance bias and registers included in this study had to be amended. These changes are minor and listed below:

- The study period has been extended from 2012 to 2013 throughout the protocol; data for 2013 will be requested (if available).
- Abstract page 3 and throughout Section 9: As the DAG has been performed, the wording in the protocol regarding the DAG has been updated to reflect. In addition, the results of the DAG have been added and the Statistical Analysis Plan (SAP) is referred to for further details.
- Abstract page 4 and Page 8, Section 9.1.3. Substudy 2: Combining the use of finasteride and dutasteride (i.e. use of any 5alpha-reductase inhibitors) has been included as a supplementary analysis and the Statistical Analysis Plan (SAP) is referred to for further details.
- Page 5, Section 6: Milestones: The timeline for this study has been taken out of protocol and added as standalone document 11 in Annex 1.
- Page 11-14, Table 2: Information on potential confounding factors: This table had to be amended to account for the exclusion of 4 variables (BRAC1 and BRAC2 gene mutations; Never having had children; Charlson's comorbidity index; Number of prescriptions) and inclusion of 2 new variables (Dietary intake of animal fat; History of bone fractures).
- Page 15, Table 3: Information on factors potentially associated with surveillance bias included in the study and data sources: This table had to be amended to account for the exclusion of 2 variables (Number of visits to general practitioner, prior benign prostatic hyperplasia therapy) and inclusion of 2 new variables (Number of prescriptions; Number of admissions).
- Page 16-17, Table 4: Registers included in this study: The names and dates of the national registers have been update and the national health service registers have been removed.
- Page 24-25, Section 11: More detail has been added to this section in compliance with the template.
- EnCePP checklist is included in Annex 2

Thank you for your attention in this matter.

PASS information

Title	Finasteride and male breast cancer – a register-based nested case-control study in Denmark, Finland, Norway, and Sweden
Protocol version identifier	Version 162.01: 10 February 2015
Date of original protocol	Version 162.00: 12 March 2014
EU PAS register number	Study not registered
Active substance	G04CB01 and D11AX10
Medicinal product	Proscar and Propecia
Product reference	Reference number(s) of centrally authorized products and/or, if possible, of nationally authorized products subject to the study See Annex 3
Procedure number	SE/H/158/01/FU/02
Marketing authorisation holder(s)	Merck sharp & Dohme B.V., Waarderweg 39, BN 2031 Haarlem, The Netherlands
Joint PASS	No
Research question and objectives	The research question is to explore whether the previously reported increased incidence rate of male breast cancer among finasteride users compared to non-users may be explained by confounding factors. The main objectives are to 1) describe finasteride users compared to non-users with respect to confounding factors and 2) analyze the effect of finasteride use on breast cancer incidence while taking account of confounding factors.
Countries of study	Denmark, Finland, Norway, and Sweden
Author	PPD National Institute of Public Health, University of Southern Denmark, Øster Farimagsgade 5A, 1353 Copenhagen, Denmark

Marketing authorisation holder(s)

Marketing authorisation holder(s)	Merck sharp & Dohme B.V., Waarderweg 39, BN 2031 Haarlem, The Netherlands
MAH contact person	PPD Regulatory Affairs EMEA Regional Center, MSD BV Molenstraat 110, 5342 CC Oss, The Netherlands Tel: PPD Fax: PPD E-mail: PPD

1. Table of Contents

2. List of abbreviations

ApEHR, Institute of Applied Economics and Health Research

ARIs, 5alpha-reductase inhibitors

BPH, benign prostatic hyperplasia

BRCA, Genes on chromosome 13 and 17 that normally helps suppress cell growth; certain mutations of these genes are associated with breast cancer and some other types of cancer

CRC, Case Review Committee (CRC)

DAG, directional acyclic graph

EU, The European Union

FDA, US Food and Drug Administration

ICD, International Classification of Diseases

MPB, male pattern baldness

NIPH, National Institute of Public Health, University of Southern Denmark

REK, Regional Ethics Committee, Norway

eSRC, External Safety Review Committee

THL, the National Institute for Health and Welfare, Finland

3. Responsible parties

Institute of Applied Economics and Health Research

- PPD
- PPD Odense University Hospital and University of Southern Denmark

National Institute of Public Health, University of Southern Denmark

- PPD
- PPD
- PPD

National scientific coordinators

- Denmark: PPD National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark

- Finland: PPD Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki. PPD School of Health Sciences, University of Tampere
- Norway: TBD
- Sweden: PPD Institute of Economics and Center for Health Economics, Gothenburg University

Expert group

- PPD Rigshospitalet, Copenhagen, Denmark
- PPD Rigshospitalet, Copenhagen Denmark
- Additional experts will be included as the project starts

4. Abstract

Title: Finasteride and male breast cancer – a register-based nested case-control study in Denmark, Finland, Norway, and Sweden.

Rationale and background: Some previous studies have suggested an association between finasteride use and male breast cancer.

Research question and objectives: To explore whether the increased incidence rate among finasteride users compared to non-users may be explained by confounding factors. The research objectives are twofold:

1. To describe finasteride users compared to non-users with respect to potential confounding factors.
2. To analyze the effect of finasteride use on male breast cancer incidence while taking account of confounding factors that may explain the previously reported increased incidence.

Study design: The study consists of two substudies.

- Substudy 1 and 1A compare finasteride users (persons with at least two prescriptions of finasteride) with non-users (persons with less than 2 prescriptions of finasteride) or persons with different levels of cumulative finasteride use with respect to potential confounding factors including survey data. Entry criterion to the group of finasteride users is redemption of the second finasteride prescription.
- Substudy 2 evaluates the association between finasteride use (exposure) and male breast cancer (outcome) taking account of confounding factors. Finasteride use is included as finasteride users versus non-users and as persons with different levels of cumulative finasteride use. Country- and age-matching will be used in substudy 2.

Population: In substudy 1 and 1A, the population comprises of all male finasteride users and a random sample of country-matched non-users aged 35+ years in the period 1995-2013 (Denmark), 1994-2013 (Finland), 2008-2013 (Norway), and July 2005-2013 (Sweden). In substudy 2 the population comprises of all male breast cancer cases and a random sample of country- and age-matched controls during the same period. Both studies used density sampling and were therefore matched on follow-up time.

Variables: Confounding variables were selected on the basis of directional acyclic graphs (DAGs) developed together with clinical experts. Finasteride use and male breast cancer are main variables. Several potential confounding factors were evaluated, e.g. benign breast disease, Klinefelter's syndrome, estrogen therapy, family history (male, female) of breast cancer, radiation exposure, alcohol intake, and socio-economic position.

Data sources: Nation-wide registers with information on prescription drugs, cancer incidence, hospital discharges, and occupation were used. Information from representative surveys on life-style factors is also included.

Study size: In substudy 1 and 1A, all finasteride users and a random sample of country-matched non-users are included. This encompasses approximately 44,000 users in Denmark, 88,000 users in Finland, 18,000 users in Norway, and 64,000 users in Sweden. For each user, one non-user aged 35+ years from the same country will be included. Substudy 1A is based on the population in substudy 1 where survey data is available. In substudy 2, all male breast cancer cases aged 35+ years will be encompassed (i.e. approximately 1000 cases) and country and aged-matched 50 controls per case will be sampled.

Data analysis: Logistic regression models will be used in both substudies. Matching on country and follow-up time (i.e. density sampling) will be accounted for in both studies, and additionally age-matching will be is performed in substudy 2. In both substudies, men aged 35 or more years will be included. For both substudies, finasteride use will be defined as either a binary variable (at least two prescriptions of finasteride versus less than two prescriptions) or a cumulative variable (2-3 packs of 98 pills, 4-6 packs, or 7+ packs of finasteride versus less than two packs of finasteride). Moreover, both substudies will include either a long follow-up time including only Denmark and Finland (1995/1994-2013) or a follow-up period including the available data from all four countries (Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (July 2005-2013). The combination of the two different definitions of finasteride use and the two follow-up periods gives four different main analyses (i.e. analyses A-D). In substudy 1, the association between potential confounders and finasteride use is analyzed and in substudy 2, the association between finasteride use and breast cancer is analyzed. Supplementary analyses will be stratified by age, be performed within a benign prostatic hyperplasia cohort, will combine finasteride and dutasteride users and will compare finasteride and alpha-blockers users. Further supplementary analyses will include alternative definitions of finasteride use (years of use, years since first use, restrict exposure to only intake of 5 mg finasteride, include persons with only one redemption of finasteride as exposed and change the requirement for new users). Furthermore, the analyses will be stratified on factors associated with surveillance bias, e.g. diagnosis of gynaecomastia, stage at diagnosis, and number of hospital admissions and, finally, latency-time analyses will be performed. Analyses of both substudies will be adjusted for differences in calendar year and analyses in Substudy 2 will additionally be adjusted for confounders.

5. Amendments and updates

This protocol (Version 162.01: 10 November 2014) has gone through very minor amendments since the original protocol (Version 162.00: 12 March 2014). These minor edits have been detailed in the coverletter.

6. Milestones

Detailed in Annex 1: Study Timeline

7. Rationale and background

Finasteride is a type II 5α-reductase inhibitor and was initially approved by the US Food and Drug Administration (FDA) in 1992 under the brand name PROSCAR as a treatment for benign prostatic hyperplasia (BPH). In 1997, the FDA approved finasteride for the treatment of male pattern baldness (MPB), under the brand name PROPECIA.

Finasteride is available in the European Union (EU) as 1 mg and 5 mg tablets in preparations and indications as follows:

- Proscar (Finasteride 5 mg, ATC code: G04CB01 (G04CB04 in Finland from 1994–1996)) for the treatment and control of BPH in patients with an enlarged prostate to cause regression of the enlarged prostate, improve urinary flow and improve the symptoms associated with BPH. This reduces the risk of acute urinary retention and the need for BPH related surgery. The daily dose is one tablet of 5 mg.
- Propecia (Finasteride 1 mg, ATC code: D11AX10) for the treatment of men with male pattern hair loss to increase hair growth and prevent further hair loss. The daily dose is one tablet of 1 mg.

The annual number of newly diagnosed male breast cancer cases is around 100 in all Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) combined (Engholm 2012). Several risk factors for male breast cancer are associated with increased estrogen and decreased androgen levels. These include testicular abnormality, benign breast disease, obesity, liver cirrhosis, Klinefelter's syndrome, gynaecomastia, estrogen therapy, and occupational exposures such as work in the perfume industry, night-shift work, and in high-temperature environments (Johansen Taber 2010, Pukkala 2009). Age of the mother at birth may also increase the risk of breast cancer.

Family history of both male and female breast cancer also affect the risk of male breast cancer. In this group genetic disposition, e.g. BRCA mutations, is associated with breast cancer (Johansen Taber 2010). Exposure to ionizing radiation is also suspected to be associated with breast cancer in men. Men with pulmonary tuberculosis, who had a large number of fluoroscopies and X-rays, have been reported to have higher incidences of breast cancer. Several life-style factors associated with female breast cancer may also be associated with male breast cancer, e.g. physical inactivity and

alcohol intake. Finally, socio-economic and urban/rural differences in male breast cancer have been reported.

Some studies have investigated an association between finasteride and male breast cancer although none of the studies reported any significantly increased risk (Lee 2004, MHRA 2009, Shenoy 2010). Most recently, a case-control study of a US patients population including 339 male breast cancer cases investigated finasteride, dutasteride (i.e. a drug within the same drug class as finasteride, ATC code G04CB02), and male breast cancer and found no association between finasteride (i.e. PROSCAR™ dosages only) and male breast cancer (3 years or more period of observation before index date: RR = 0.75, 95% CI: 0.27 – 2.10; 365 days cumulative therapy: RR = 1.03, 95% CI: 0.45 – 2.37) (Bird et al, 2013). A register-based cohort study with data from Denmark, Finland, Norway, and Sweden was conducted by the applicants to study the potential link between finasteride use and incident male breast cancer (results not published) (Stage 1 Study report, unpublished). Based on data from nation-wide registers on drug prescriptions and cancer incidence, the study reported an increased incidence of breast cancer among male users of finasteride compared to non-users (incidence rate ratio, 1.44; 95%CI, 1.11-1.88). This study was much larger than any previous study and the finding of a significantly increased incidence rate has not been reported in any of the previous studies. When restricting the analyses to Denmark and Finland with the longest observation period, an increased breast cancer incidence rate was also observed, most pronounced in Denmark. Higher prevalence of finasteride use was observed in Finland compared to Denmark. Furthermore, Danish users of finasteride had a 1.23 times higher mortality rate compared to Finnish finasteride users. These two patterns indicate that finasteride users in Denmark are more selected than in Finland, which could indicate that confounding factors may be different between the two countries. Statistical adjustment was made for age and calendar year, but concerns have been raised whether adjustment for other risk factors for breast cancer may alter the association found.

In the present study further information on confounding factors will be included to compare finasteride users and non-users (investigating finasteride users defined by both a binary variable and a cumulative variable) and to evaluate whether the reported association between finasteride use and male breast cancer can be explained by confounding factors. The main analyses will be performed for both Denmark and Finland to evaluate the effect of finasteride in the two countries with longest follow-up (1994-2013 for Finland and 1995-2013 for Denmark) and, alternatively, for all four countries (Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013) and Sweden (July 2005-2013)). The analysis only including Finland and Denmark will be performed since follow-up time is limited for Sweden and Norway which increases the influence of truncation and makes latency analyses more difficult to perform.

8. Research question and objectives

The research question is to further explore whether the increased male breast cancer incidence among finasteride users compared to non-users may be explained by confounding factors. The research objectives are twofold:

1. Describe finasteride users compared to non-users with respect to potential confounding factors (exploratory variables).
2. Analyze the effect of finasteride use on male breast cancer incidence while taking account of confounding factors decided in a DAG analyzing the association between finasteride use and male breast cancer.

The hypotheses are:

1. There is a systematic difference between finasteride users and non-users for potentially confounding factors previously reported to be associated with finasteride use or male breast cancer incidence.
2. The previously found increased incidence of male breast cancer among finasteride users is explained by confounding factors.

9. Research methods

9.1. Study design

The first step was developing a DAG for the association between finasteride use and male breast cancer. This development highlighted factors associated with finasteride use, factors that are a consequence of finasteride use, and factors associated with male breast cancer risk. The DAG pinpointed which variables to include in the analysis of the association between finasteride use and male breast cancer (substudy 2) and which should be left out. All factors associated with finasteride use or male breast cancer will be included in the descriptive substudy 1.

9.1.1. Substudy 1

In substudy 1, persons with at least two prescriptions of finasteride and persons with less than two prescriptions of finasteride and persons with different levels of cumulative finasteride use (0-1 packs of 98 pills, 2-3 packs, 4-6 packs, and 7+ packs) are compared with respect to potential confounding factors described in section 9.3. This study utilizes a new user design by excluding finasteride users with the first redemption of finasteride within the first 6 months of registration. For each male we sample one male non-user using density sampling (Rothman 2008). Specifically, when one man redeems his second finasteride prescription we will sample one other man alive in the same country at that particular day who has redeemed less than two finasteride prescriptions before or at that particular day. We will restrict the control selection to men of age 35 and above, since the use of finasteride is almost entirely restricted to this age span. This man will be given an index date and information on confounding factors will be extracted for the period before the index date. Using this

sampling scheme the odds ratios estimated in the logistic regression model can be interpreted as an incidence rate ratio of finasteride use for persons exposed to confounding factors compared to non-exposed (Rothman 2002, Rothman 2008). For confounders with more than two categories, the odds ratios estimated can be interpreted as incidence rate ratios for each category compared to a reference group. Several supplementary analyses will be performed including alternative definitions of finasteride use, comparison of finasteride and alpha-blockers users, age-stratified analyses, and stratified on factors associated with surveillance bias and latency. The supplementary analyses are further described in section 9.7.

The matching criteria of substudy 1 are:

- Country
- Follow-up time (density sampling)

9.1.2. Substudy 1A

In substudy 1A finasteride users will be compared with non-users with respect to self-reported life-style factors as obesity, alcohol intake, and physical inactivity also listed in section 9.3. In this study, we link national surveys including self-reported information on these potential confounders with finasteride users and non-users, either defined by use of a binary or a cumulative measure of finasteride use (substudy 1 data).

9.1.3. Substudy 2

In substudy 2, the effect of either finasteride use versus non-use or cumulative finasteride use on male breast cancer is analyzed taking account of the confounding factors selected by the previously developed DAG. In a situation where results from substudy 1 and 1A show an important imbalance between finasteride and non-finasteride users that is not yet included in the DAG, we will reconsider the DAG by including or excluding arrows as appropriate and use the updated minimum sufficient confounder set for confounder adjustment in substudy 2. Breast cancer cases will be identified in the national cancer registers, where diagnosis of cancer is carefully evaluated by medical experts (Gjerstorff 2011). The study will be a density sampled case-control study, where each male breast cancer case will be country- and age-matched to controls (Rothman 2002). We will select 50 controls per case (see calculation of minimal detectable OR in section 9.5). This substudy will also utilize a new user design by excluding finasteride or dutasteride users with the first redemption within the first 6 months of registration. The primary analysis will exclude users of dutasteride from cases and controls. Several supplementary analyses will be performed, including alternative definitions of finasteride use, combining use of finasteride and dutasteride (i.e. use of any ARI), comparison of finasteride and alpha-blockers users, analysis nested within a cohort of patients with benign prostatic hyperplasia (BPH), country-specific and age-stratified analyses, and stratified on factors associated with surveillance bias and latency. The supplementary analyses are further described in section 9.7.

The matching criteria of substudy 2 are:

- Country
- Age
- Follow-up time (density sampling)

One supplementary analysis is the comparison of use of alpha-blocker and use of finasteride. This analysis is done by analyzing the association between finasteride use and male breast cancer among non-users of alpha-blockers and the association between alpha-blockers and male breast cancer among non-users of finasteride. If the risk estimates of finasteride and alpha-blockers on male breast cancer will be comparable in these two analyses, this may support that unmeasured confounding by indication is present, while if the risk estimate of finasteride is stronger than alpha-blockers this may indicate that confounding by indication does not strongly influence the association between finasteride use and male breast cancer. This analysis is only included as a supplementary analysis because the indication for treatment with alpha-blockers and finasteride may be different in the Nordic countries and because of lack of power when excluding persons exposed to either finasteride or alpha-blockers.

Another supplementary analysis will be within a cohort of men with diagnosis or treatment for benign prostatic disease termed the benign prostatic hyperplasia (BPH) cohort. The development and definition of diagnosis and treatment of relevant benign prostatic diseases will be done together with clinical experts.

9.2. Setting

The two substudies consist of two study populations:

The substudy 1 consists of finasteride users (at least two prescriptions of finasteride) during the study period compared with non-users (less than two prescriptions of finasteride). For each user we sample one country-matched non-user alive and living in the populations at that given day. The study period is 1995-2013 in Denmark, 1994-2013 in Finland, 2008-2013 in Norway, and July 2005-2013 in Sweden. Data will be available until and including 2012 for all countries, for some countries also for 2013. Data will be applied for including 2013 and used if available. During the analysis phase we will also compare users with a higher consumption of finasteride with users with lower consumption and non-users. This is the reason for not using age-matching in this study because by age-matching we would need several non-users for the same finasteride user as the user accumulates finasteride. Instead we will adjust our analysis for differences in age.

In substudy 1A we will include all finasteride users (substudy 1 data) who previously have participated in a survey. Each finasteride user will be compared to sampled non-users who previously have participated in a survey. We will include the most recent information on life-style factors.

The substudy 2 is designed as a density sampled case-control study (Rothman 2002). Each male breast cancer case during follow-up (1995-2013 in Denmark, 1994-2013 in Finland, 2008-2013 in Norway, and July 2005-2013 in Sweden) will be country- and age-matched to controls at risk of breast cancer on the date of breast cancer diagnosis (index date). For each case we will sample 50

controls (see calculation of minimal detectable OR in section 9.5). Data will be available until and including 2012 for all countries, for some countries also for 2013. Data will be applied for including 2013 and used if available.

9.2.1. Inclusion criteria

Substudy 1

- Males residing in either Denmark, Finland, Norway, or Sweden on the index date
- Aged 35 years and older
- Finasteride user group: Men who have redeemed at least two prescriptions of finasteride in the study period (either as one group or divided into three groups, i.e. 2-3 packs of 98 pills, 4-6 packs, and 7+ packs)
- Non-finasteride user group: Men who have redeemed less than two prescriptions of finasteride in the study period

Substudy 2

- Males residing in either Denmark, Finland, Norway, or Sweden on the index date
- Aged 35 years and older
- Cases: Men with a diagnosis of primary breast cancer (see section 9.2.3 Primary breast cancer case definition)
- Controls: Men without a diagnosis of breast cancer at index date

9.2.2. Exclusion criteria

Substudy 1

- None

Substudy 2

- Previous cancer diagnosis or treatment for cancer except non-melanoma skin cancer
- Previous prostatectomy
- Finasteride or dutasteride use (dutasteride is a drug in the same class as finasteride) within first 6 months of registration in the prescription registers (new user design).

9.2.3. Primary breast cancer case definition

A primary breast cancer case will be defined as one that is recorded in the cancer registers, as per ICD-10-CM (C50).

Information on the macro- and microscopic basis of breast cancer diagnosis is available from the Nordic cancer registers. A diagnosis in the cancer registers is based on the combination of information from the national patient registers, pathology registers and cause of death registers. The vast majority of cases listed in those registers are based on invasive examinations (surgery and autopsy) and histological confirmation. In case of incomplete or controversial information, requests

for further information are sent to hospitals and physicians who failed to report complete information (Gjerstorff, 2011; Pukkala, 2011). The use of multiple data sources secures a high degree of completeness of the cancer registers.

To characterize the male breast cancer cases, a descriptive analysis will be performed. This analysis will consist of information on pathology code (per microscopic-based evidence of primary malignant neoplasia of the breast which was indicated by histology and/or cytology) and intervention against the primary breast cancer (i.e. surgery, radiation, and/or chemotherapy).

9.3. Variables

In substudy 1, the dependent variable is either redemption of two or more finasteride prescriptions and the comparison group of males with less than two prescriptions sampled from the population or cumulative finasteride use (0-1 packs of 98 pills, 2-3 packs, 4-6 packs, and 7+ packs of finasteride). Variables that may be associated with surveillance bias will also be examined. The explanatory variables in the analysis are described in Table 2. For substudy 1A we will study life-style related risk factors. In substudy 2, the outcome is first diagnosis of male breast cancer and controls are sampled from the population. The exposure variable is either redemption of two or more finasteride prescriptions and the comparison group of males with less than two prescriptions sampled from the population or cumulative prescriptions of finasteride (0-1 packs of 98 pills of 5 mg, 2-3 packs, 4-6 packs, and 7+ packs) in the period before breast cancer diagnosis. The potential confounding variables are described in Table 2, but in the analysis only variables in the selected minimum sufficient confounder set in the DAG will be included (described in more detail in Statistical Analysis Plan (SAP)). Furthermore, variables that may be associated with surveillance bias will be studied (Table 3).

For finasteride exposures, the information in the registers reflects the fact that medication prescribed has been dispensed to and paid for by the patient. Whether the medication has actually been consumed, though, is not known.

Table 2. Information on potential confounding factors that will be included in substudy 1 and may be included in the substudy 2 depending on the final DAG developed

Confounding factors	Explanation	Data source (also see Table 4)	Substudy 1 (1)	Substudy 2 (2)
Increased estrogen and decreased androgen levels				
- Testicular-abnormalities / disorders	Testicular disorders could influence the estrogen-androgen ratio increasing risk of breast cancer. The only complication is that most patients with testicular disorders will have been treated as children and this may not be available in the hospital registers	National Patient Registers, including but not limited to orchitis and cryptorchidism	Any diagnosis before finasteride use	Any diagnosis before breast cancer index date
- Benign breast disease	Benign breast disease is associated with breast cancer risk	National Patient Registers	Any diagnosis before finasteride use	Any diagnosis before breast cancer index date
- Obesity	Obesity and morbid obesity influence the estrogen-androgen ratio. We include contacts to the hospital system for morbid obesity and self-reported height and weight from nation-wide registers	National Patient Registers including the following disorders: Obesity (ICD-10, E66). Furthermore self-reported height and weight from nation-wide surveys	Any diagnosis before finasteride use or self-reported BMI before finasteride use	Only register-based diagnoses on morbid obesity included. Any diagnosis before breast cancer index date
- Liver cirrhosis	Liver cirrhosis influences the conversion of sex-hormones which could influence the breast cancer risk	National Patient Registers. Include the following disorders: Alcoholic cirrhosis of liver (ICD-10, K70.3), toxic liver disease with fibrosis and cirrhosis (K71.7), and liver fibrosis and cirrhosis (K74)	Any diagnosis before finasteride use	Any diagnosis before breast cancer index date
- Klinefelter's syndrome	Rare syndrome that causes abnormal development of the testicles due to low production of male hormones and high production of female hormones. The syndrome is a risk factor for breast cancer. Very few patients with this syndrome and may therefore not be relevant in the present study	National Patient Registers including the ICD-10 code for the syndrome-me: Q98.4	Any diagnosis before finasteride use	Any diagnosis before breast cancer index date

Table 2. Information on potential confounding factors that will be included in substudy 1 and may be included in the substudy 2 depending on the final DAG developed

Confounding factors	Explanation	Data source (also see Table 4)	Substudy 1 (1)	Substudy 2 (2)
- Estrogen therapy	Medications that may influence the exposure to estrogen will be included.	National Prescription Registers	At least two redemptions before finasteride use	At least two redemptions before breast cancer index date
- Occupational exposures	Occupational exposures in the perfume industry, in high-temperature environments and night-shift work may increase the exposure to estrogens	Denmark: Register-based labour force Finland: Censuses Norway: Censuses Sweden: Register-based labour force behavior; place of work; employer etc. (source: LISA)	Labour market affiliation in any of these occupations two calendar years before finasteride use	Labour market affiliation in any of these occupations two calendar years before breast cancer index date
Family exposures				
- Family history of breast cancer	Family history of breast cancer (male, female) is associated with breast cancer	Civil registration systems and cancer registers. The information on mothers is available for cohorts from 1960 in Denmark (Pedersen 2006) and from October 1953 in Finland. For Sweden, it is possible – in principle – to identify biological parents via RTB and then to look for each individual in the Cancer register. The Cancer registry started in 1958 in Sweden.	Any familial breast cancer diagnosis before finasteride use	Any familial breast cancer diagnosis during the whole registration period

Table 2. Information on potential confounding factors that will be included in substudy 1 and may be included in the substudy 2 depending on the final DAG developed

Confounding factors	Explanation	Data source (also see Table 4)	Substudy 1 (1)	Substudy 2 (2)
Ionizing radiation and cancer treatment				
- Radiation exposure including men treated with radiotherapy for pulmonary tuberculosis	X-rays of the chest may increase risk of breast cancer. SKS-code: UXRC including UXRC40/UXRC45 (mammography). Will also include CAT scans	National Patient Registers	Any treatment before finasteride use	Any treatment before breast cancer index date
Life-style factors				
- Alcohol intake	Alcohol intake is a risk factor for breast cancer	Nation-wide surveys	Intake five years before finasteride use	Self-reported information will not be included
- Physical inactivity	Physical inactivity is a risk factor for breast cancer	Nation-wide surveys	Activity five years before finasteride use	Self-reported information will not be included
- Dietary intake of vegetables and fruit	Vegetable and fruit intake a preventive factor for breast cancer	Nation-wide surveys	Intake five years before finasteride use	Self-reported information will not be included
- Dietary intake of animal fat	Animal fat may increase risk of breast cancer	Nation-wide surveys	Intake five years before finasteride use	Self-reported information will not be included

Table 2. Information on potential confounding factors that will be included in substudy 1 and may be included in the substudy 2 depending on the final DAG developed

Confounding factors	Explanation	Data source (also see Table 4)	Substudy 1 (1)	Substudy 2 (2)
Socio-economic differences				
- Socio-economic position	Finasteride users have higher socio-economic position. We include socio-economic position using categorizations used by the national statistical offices	Denmark: Register-based labour force Finland: Censuses Sweden: Register-based labour force data (source: LISA)	Socio-economic position the year before finasteride use	Socio-economic position the year before breast cancer index date
- Living as a single man		Civil registration systems	Cohabitation status the year before finasteride use	Cohabitation status the year before breast cancer index date
- Urban / rural differences	Men living in urban areas may experience higher breast cancer incidence, e.g. due to elevated exposure to traffic-related air pollution, light at night or higher alcohol intake	Civil registration systems	Information the year before finasteride use	Information the year before breast cancer index date
Other factors				
- Diabetes	Potentially novel finding (Brinton et al 2014)	National patient registers	Index up to 10 years before first finasteride use	Index up to 10 years before breast cancer index date
- History of bone fractures	Brinton et al 2014 (reported in this study among those diagnosed with male breast cancer at older ages)	National patient registers	Index up to 10 years before first finasteride use	Index up to 10 years before breast cancer index date

(1) This column describes how the information is included in substudy 1.

(2) This column describes how the information is included in substudy 2.

Table 3. Information on factors potentially associated with surveillance bias included in the study and data sources

Factors associated with surveillance bias	Explanation	Data source (also see Table 4)	Substudy 2
- Gynaecomastia	One side-effect of finasteride use is gyneaecomastia. Gyneaecomastia is associated with breast cancer	National Patient Registers including the ICD-10 code N62	Any diagnosis before breast cancer index date
- Use of drugs that cause gynaecomastia	Antiandrogens other than finasteride and dutasteride (bicalutamide, flutamide, nilutamide) Antihypertensives (Spironolactone) Antiretrovirals (protease inhibitors (saquinavir, indinavir, nelfinavir, ritonavir, lopinavir) and nucleoside reverse transcriptase inhibitors (stavudine, zidovudine, lamivudine) Environmental exposures (phenothrin) Exogenous hormones (estrogen, rednisone (adolescent boys)) Gastrointestinal agents (histamine$_2$-receptor blockers (cimetidine))	Prescription registers	At least two redemptions before breast cancer index date
- Number of prescriptions	Indication of morbidity	Prescription registers	Count up to 10 years before breast cancer index date
- Number of surgeries	Indication of morbidity	National Patient Registers	Any number of surgeries before breast cancer index date
- Number of admissions	Indication of morbidity	National Patient Registers	Any number of admissions before breast cancer index date
- Urinary retention	Associated with finasteride use	National patient registers	Any diagnosis before breast cancer index date
- Cancer stage	Earlier cancer stage among finasteride users may that the finasteride users were followed closer by medical staff	Cancer registers	Cancer stage of the index case

Ideally the chronological order of confounders, exposure (finasteride use), and outcome (male breast cancer diagnosis) should be that the confounding factors should be measured before the first prescription of finasteride and finasteride use should be prescribed before the breast cancer diagnosis. In accordance with the chronological order mentioned above, potential confounding factors will be measured before the first prescription of finasteride use in substudy 1 (Table 2, the "substudy 1" column). However, in substudy 2 it is not possible to measure confounders before exposure for persons without exposure, i.e. non-exposed cases and controls. Therefore, it is necessary to include confounder information during the same period as exposure collection (the "substudy 2" column). The DAG developed clarified whether a potential confounder variable indeed is a confounder or it is an intermediate variable.

The variables presented in Table 3 may be associated with surveillance bias in that patients with these factors may have an increased probability of diagnosis of breast cancer because of more careful surveillance. The analyses in substudy 2 will be stratified on these factors to detect whether an increased odds ratio could be explained by surveillance bias (see section 9.7 below).

Information on date of birth, date of death, sex and date of immigration and emigrations will also be obtained.

9.4. Data sources

The sampling populations are the Danish, Finnish, Norwegian, and Swedish male populations aged 35 years or older. We utilize the nation-wide registers of prescriptions, cancer incidence, contacts to the secondary and tertiary hospital system, the civil registration system, and registers on occupational group. The registers cover different periods (see Table 4 below), but all registers have registration for the period 1995-2013 for Denmark, 1994-2013 for Finland, 2008-2013 for Norway, and July 2005-2013 for Sweden. The limiting factor here is the year from which medical intervention codes are available (Table 4). Linkage between the registers is possible due to the unique individual identification numbers (Gissler 2004, Thygesen 2011). We will also include national health surveys conducted in each of the countries several times during follow-up.

Table 4: Registers included in the study

Country	Register	Registration period
Denmark	Prescription register	1995-2013
	Cancer register	1943-2013
	National patient register	1977-2013 (surgeries since 1977 and outpatient contacts since 1995)
	Civil registration system	1968-2013
	Register-based labour force statistics (RAS statistics)	1980-2013
	National Health Surveys	1994, 2000, 2005 and 2010
Finland	Prescription register	1994-2013
	Cancer register	1953-2013
	Hospital patient Register	1967-2013 (surgeries since 1986 and outpatient contacts since 1998)
	Civil registration system	1967-
	Censuses including information on occupational group	1995, 2000, 2005 and 2010
	National Health Surveys	1972, 1977 onwards
Norway	Prescription register	2004-2013
	Cancer register	1951-2013
	Hospital patient Register	2008-2013
	Civil registration system	1968- 2013
	Register on labour force statistics (AaNAV)	2000 (2007)- 2013
	National Health Surveys	1994-2013
Sweden	Prescription register	July 2005-2013
	Cancer register	1958-2013
	Patient Register	1987- 2013
	Civil registration system (Register over totalbefolkningen)	1968- 2013
	Register on labour force statistics (LISA)	1990- 2013
	National Health Surveys (The Swedish Survey of Living Conditions interviews)	2000-2013

Information from the prescription registers and the cancer registers have been validated (Gjerstorff 2011, Kildemoes 2011, Pukkala 2011). The national patient registers include diagnostic and treatment information for patients treated at the secondary and tertiary hospital level (Lynge 2011, Pukkala 2011). Clinical experts have been consulted on how to include this information. The codes are described above in Table 2. Information on date of birth, immigration, emigration, and death were obtained from the civil registration systems (Pedersen 2011, Pukkala 2011). Information on occupational status will be obtained from registers on attachment to the labor market (Petersson 2011, Pukkala 2009).

We will also include information from population surveys conducted in Denmark (Christensen 2012), Finland (Pukkala 2011), Norway (Næss 2008), and Sweden. The surveys are nation-wide representative health surveys including information on life-style factors. We will link this information to the finasteride users and non-users sampled in substudy 1A.

9.5. Study size

The substudy 1 includes all finasteride users and a random sample of country-matched non-users. In the previous study of finasteride use and male breast cancer (Stage 1 Study report, unpublished) the number of unique finasteride users (one or more prescriptions of finasteride) was 56,406 for Denmark in the period 1995-2009, 111,820 for Finland in the period 1997-2010, 22,345 for Norway in the period 2004-2009, and 79,712 for Sweden in the period July 2005-2009. The study also estimated that 76-85% of the finasteride person-time was for users with at least two prescriptions of finasteride. We therefore estimate that approximately 214,000 persons will have at least two prescriptions of finasteride and hence count as finasteride users in the present study.

The minimum detectable odds ratio (OR) is calculated for different values of proportion of non-finasteride users exposed to the confounder of relevance.

If we make the following assumptions, we can calculate the minimum detectable OR:

- Power = 90%
- Alpha = 5%
- Two-sided test
- 214,000 finasteride users
- 214,000 non-users

If we vary the proportion of non-finasteride users exposed to the confounder we can estimate the minimum detectable odds ratio (Table 5).

Table 5. Minimal detectable OR for substudy 1

The proportion of non-finasteride users exposed to the confounder	Minimum detectable OR
1% / 99%	1.102
5% / 95%	1.046
10% / 90%	1.033
25% / 75%	1.023
50%	1.020

We conclude that the power of substudy 1 is very high even when only one non-user is included per user. Even under the assumption of a power of 90% we will be able to detect odds ratios of 1.10 for very rare (or very common) confounders.

Substudy 1A includes a linkage between the prescription registers and national health surveys. The Danish National Health Survey consists of cross-sectional surveys conducted in 1994, 2000, 2005, and 2010 among persons aged 16 years and older. The number of participants in the surveys was 16,688, 14,566, and 15,165, respectable, which corresponds to approximately 0.4% of the population. Based on the previous study (Stage 1 Study report, unpublished), we assume that 3% of males are finasteride users. This means that we can assume that approximately 240 finasteride users also have participated in each of the surveys. In Finland, the National FINRISK Study has been conducted since 1972 every five years, first in Eastern Finland, and later on in five areas in Finland (Helakorpi 2008; Vartiainen et al 2010). The main aim of the FINRISK Study is to collect data on and monitor levels of risk factors of cardiovascular diseases and other non-communicable diseases among the Finnish population. Participants from each study area have been selected by using stratified random sampling. The participants were 25 to 64 years (since 1997 25 to 74 years) old at baseline. In Norway, the Cohort of Norway (CONOR) includes information from about 173,000 respondents in the period from 1994 to 2003 (Næss 2008). The participants answered a questionnaire and underwent a physical examination. The Swedish Survey of Living Conditions, Statistics Sweden, interviews about 10,000 respondents annually (some changes over time have occurred). Each year between 2000 and 2012 about 7,500–10,000 respondents were interviewed (respondents were 16–84 years of age).

Substudy 2 includes all male breast cancer cases and a country- and age-matched sample of controls. The number of male breast cancer cases was 365 in Denmark, 236 in Finland, 101 in Norway, and 200 in Sweden in the previous study (Stage 1 Study report, unpublished). The number of finasteride users who developed male breast cancer after first purchase of finasteride was 29 in Denmark, 26 in Finland, 1 in Norway, and 7 in Sweden. In this study, the sample will slightly increase because of longer follow-up. We expect approximately 1000 cases in the present study. The exposure variable in substudy 2 is either finasteride use (2+ prescriptions) versus less than two prescriptions or cumulative finasteride use (0-1 packs of 98 pills of 5 mg, 2-3 packs, 4-6 packs, and 7+ packs). We expect the 1000 cases will be distributed in the binary finasteride use categories as

follows: 948 used 0-1 packs of 98 pills and 52 used 2+ packs of 98 pills. For the four categories of cumulative finasteride use the number of cases will be: 948 cases used 0-1 packs of 98 pills, 20 cases used 2-3 packs, 11 cases used 4-6 packs and 21 cases used 7+ packs.

Based on the following assumptions, the minimal detectable OR for a comparison of exposure 7+ packs versus 0-1 packs can be calculated for a varying number of controls per case and assuming different proportions of exposed controls in a matched case-control study (Dupont, 1988 as implemented in STATA version 12 in the SAMPSI_MCC procedure):

- Power = 80 %
- Alpha = 5%
- Two-sided test
- Number of cases: 969
- Number of controls per case varies: 10, 25, 50, 100
- Proportion of exposure individuals among controls varies: 0.3%, 0.5%, 1%, 1.5%, 2%, 3%, 4%
- Correlation of exposure between pairs in the case-control set at 0.1

For a varying proportion of exposed controls we can estimate the minimum detectable OR for a comparison of exposure 7+ packs versus 0-1 packs of substudy 2 for 10, 25, 50 and 500 controls per case, respectively (Table 6). Similar minimum detectable OR is expected for a comparison between exposure 0-1 packs versus the two other exposure groups (2-3 packs, 4-6 packs).

Table 6. Minimal detectable OR for substudy 2

The proportion of exposed controls	Minimum detectable OR			
	1:10 controls	1:25 controls	1:50 controls	1:500 controls
0.3%	3.29	3.15	3.10	3.05
0.5%	2.69	2.59	2.56	2.53
1%	2.13	2.08	2.06	2.04
1.5%	1.91	1.86	1.85	1.84
2%	1.77	1.74	1.73	1.72
3%	1.62	1.60	1.59	1.58
4%	1.54	1.52	1.51	1.50

This analysis supports that the minimum detectable OR does not vary remarkably by number of controls and 50 controls per case is assumed to be an adequate number of controls to include in substudy 2. The minimum detectable OR, when sampling 50 controls per case, is estimated to range from 2.56 if 0.5% of the controls are exposed to 1.51 if 4% of the controls are exposed.

9.6. Data management

The handling of data includes seven steps.

1. All national scientific coordinators will apply relevant agencies for permission to perform the study and to get access to data, including Statistics Denmark/Statistics Finland/Statistics Norway/Statistics Sweden, and other relevant agencies to search the prescription registers for all purchases of finasteride and the cancer registers for all male breast cancer cases.
2. All national scientific coordinators will facilitate the construction of the study populations:
    - Study population consisting of all finasteride users and a sample of comparable non-users.
    - Study population consisting of male breast cancer cases and controls during the study period.
    - Both study populations will be sampled via density sampling based on the description and SAS code derived by the Danish scientific coordinator and agreed upon by the national scientific coordinators.
3. All national scientific coordinators are responsible of acquiring and validating the datasets and will explore how the datasets can be combined with the five registers described in section 9.4. Data control includes - but is not restricted to - check for legal values for each categorical variable, check of consistency between dates (at least date of birth before all other dates and date of death after all dates), and check and advice on the handling of missing data. All national scientific coordinators produce a data control report describing the checks performed and describing how the final dataset should be constructed from the registers received including reasons for modifications and exclusions. In this process all national coordinators have to agree on the reasons for exclusion, e.g. missing value on crucial variables, chronological errors in the relation between dates, non-legal values of categorical variables, and extreme values of continuous variables (see Statistical Analysis Plan (SAP)).
4. The datasets from Finland, Norway, and Sweden are transferred to Statistics Denmark where all subsequent data handling is done by the Danish scientific coordinator.
5. The Danish scientific coordinator links the data as described by the document developed by all national scientific coordinators and the data sets from all countries will be joined into a combined analysis dataset. Relevant variables will be derived.
6. The Danish scientific coordinator will assess the data validity of all countries by logical checks, examination of extreme values, and missing data. It is important that identification numbers are maintained to facilitate linkage back to the original data sets to be able to check the data and for the sake of transparency.
7. Data analysis and evaluation of the hypotheses described above (section 8) using SAS version 9.3 will be performed by the Danish scientific coordinator. Please also see section 9.7.

9.7. Data analysis

In the previous study (Stage 1 Study report, unpublished) we found a few inconsistencies, e.g. wrong chronology of dates and missing data for important variables. These inconsistencies accounted for

few records and were removed from the analyses. If the same pattern is observed in this study we will also remove persons with inconsistencies to ensure complete data in analysis. Initially, a DAG of the association between finasteride use and male breast cancer including potential confounders was derived by the Danish national investigators and the clinical expert group (Greenland 1999). The DAG clarified whether the potential confounders listed in Table 2 are confounders, colliders, or intermediate variables. Based on this clarification, it was decided which potential confounders will be included in substudy 2. In a situation where results from substudy 1 and 1A show an important imbalance between finasteride and non-finasteride users that is not yet included in the DAG, we will reconsider the DAG by including or excluding arrows as appropriate and use the updated minimum sufficient confounder set for confounder adjustment in substudy 2. All factors associated with finasteride use of male breast cancer will be included in the descriptive substudy 1. Please refer to Statistical Analysis Plan (SAP).

For both substudies finasteride use will be defined as either a binary variable (at least two prescriptions of finasteride versus less than two prescriptions) or a cumulative variable (2-3 packs of 98 pills, 4-6 packs, or 7+ packs of finasteride versus less than two packs of finasteride). Moreover, both substudies will include either a long follow-up time including only Denmark and Finland (1995/1994-2013) or a follow-up period including the available data from all four countries (Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (July 2005-2013). The combination of the two different definitions of finasteride use and the two follow-up periods gives four different main analyses (A-D) also described in Annex 4: A (long follow-up and binary finasteride use); B (long follow-up and cumulative finasteride use); C (available follow-up period for all four countries and binary finasteride use), and D (available follow-up period for all four countries and cumulative finasteride use)

In substudy 1, logistic regression will be performed by comparing potential confounding factors for finasteride users compared to non-users and between levels of cumulative finasteride use. The main analyses will include these two definitions of finasteride use among either long follow-up data from Denmark (1995-2013) and Finland (1994-2013) or all available data including all four countries (Denmark, Finland, Norway (2008-2013) and Sweden (July 2005-2013)), i.e. analyses A-D.

Ten supplementary analyses will be performed for substudy 1 (please also see Annex 4 for a table of the analyses) to further elaborate the associations between potential confounders and finasteride use:

1. Age-stratified analysis (above and below 45 years of age)
2. Analysis within the benign prostatic hyperplasia cohort
3. Analysis comparing alpha-blockers users with finasteride users
4. Include years of finasteride use as dependent variable (1-3, 4-5 and 6+ years)
5. Include years since first finasteride use as dependent variable (below 1 year, 1-2 years, 3-4 years and 5+ years)
6. Only include 5 mg finasteride as finasteride users
7. Include persons who only redeem one prescription in the user group

8. Change the requirement for new user by excluding finasteride users with first redemption of finasteride within the first 2 years of follow-up
9. Stratify the analysis by variables associated with surveillance bias
10. Latency analyses by inferring 1 and 2 years of lag time between confounding factors and finasteride use

In substudy 1A, the same main analyses as in substudy 1 will be done, i.e. we will include dependent variables as either a binary variable or as a cumulative variable in either Denmark and Finland or in all four countries (i.e. analyses A-D).

In substudy 2, conditional logistic regression will be performed by comparing male breast cancer cases with controls in respect to either finasteride users versus non-users or cumulative finasteride use and including confounding factors in the analysis. We will include confounding factors established by the DAG developed before substudy 1. We will consider using propensity score adjustment to take account of the numerous confounding factors more efficiently. The propensity score distribution will be plotted to look at overlap. If there is not sufficient overlap, then propensity score adjustment is not feasible. If the overlap is sufficient, we will use propensity score to adjust for multiple confounders. Conditional logistic regression will be performed to take account of the country- and age-matching. The analyses will either be performed with long follow-up data from Denmark (1995-2013) and Finland (1994-2013) or including all available follow-up time (Denmark, Finland, Norway (2008-2013) and Sweden (July 2005-2013) as described above (i.e. analyses A-D).

Eleven supplementary analyses will be performed for substudy 2 (please also see Annex 4 for a table of the analyses) to further elaborate the associations between finasteride use and breast cancer:

1. Age-stratified analysis (above and below 45 years of age)
2. Analysis within the benign prostatic hyperplasia cohort
3. Analysis comparing alpha-blockers users with finasteride users
4. Analysis of combined finasteride or dutasteride use (i.e. use of any ARI)
5. Include years of finasteride use as exposure (1-3, 4-5 and 6+ years)
6. Include years since first finasteride use as exposure (below 1 year, 1-2 years, 3-4 years and 5+ years)
7. Only include 5 mg finasteride as finasteride users
8. Include persons who only redeem one prescription as exposed
9. Change the requirement for new user by excluding finasteride users with first redemption of finasteride within the first 2 years of follow-up
10. Stratify the analysis by variables associated with surveillance bias
11. Perform latency analyses by inferring 1 and 2 years of lag time between exposure and confounders and breast cancer

All analyses will be programmed by two researchers independently to ensure complete agreement of the number of men, finasteride use (both binary and cumulative), number of cases, and the results of the analyses.

9.8. Quality control

The study is register-based and data quality is therefore difficult to ascertain directly. Previous studies have evaluated the validity of the central registers, e.g. the prescription registers and the cancer registers (Jensen 2002, Kildemoes 2011, Pukkala 2011). These studies in general support that the validity and completeness of the data sources are high.

The statistical analyses will be performed on servers at Statistics Denmark. The programming will be performed by two researchers independently limiting the programming errors. The statistical programs will be stored at the servers at Statistics Denmark.

9.9. Limitations of the research methods

A limitation of the study is the comparison of users with non-users, where the observed association may be influenced by confounding by indication since finasteride users will have more comorbidities and may have more contacts with medical staff. This could result in higher incidence of breast cancer among finasteride users than among a random sample of males. In the analyses, we try to capture this bias by stratifying the analyses by factors associated with surveillance bias, by adjusting for comorbidities, and by doing analysis of the separate effects of alpha-blockers and finasteride.

A minor limitation related to estimation of finasteride use is the prescription registers, which contain information on redeemed medications, and no information on the actual consumption of drugs. This is the reason for only categorizing persons with at least two prescriptions of finasteride as exposed, because these persons with repeated purchases of finasteride are more likely to also have used most of the drugs.

For several of the confounding factors, the information is only based on one or a few ICD-10 codes. This may result in under-estimation of the true prevalence of several of the confounding factors, e.g. obesity. We think this under-estimation will not be related with finasteride use thereby mimicking non-differential misclassification resulting in conservative observed associations for substudy 1. For other of the possible confounding factors the information is based on statistical classification systems, e.g. industrial classification systems, which may also be misclassified. We think this will also result in an under-estimation of the association between confounding factors and finasteride use. Whether this underestimation will result in an over- or underestimation of the association between finasteride use and breast cancer cannot be predicted.

Truncation is also a potential bias in the study meaning that we have no information on confounding factors, finasteride use, or cancer incidence before the start of registration of each of these factors. This is most pronounced for finasteride use, since we do not know whether a finasteride user in the first year of registration in Denmark and Finland and for more than a decade in Norway and Sweden is a long-term user (prevalent user) or a first-time user (incident user). This is only a minor limitation in Denmark and Finland, since finasteride was first approved in 1992, but is important to consider for Norway and Sweden. We will evaluate the influence of this limitation by excluding finasteride users in the first year of registration as a supplementary analysis to ensure that users in the second year are incident users.

In substudy 1A, only participants of the national surveys will be included. This may introduce selection bias in that the participants may not be representative of all finasteride users and non-users.

10. Protection of human subjects

This is an observational study with no administration of any therapeutic or prophylactic agent. Patients observed in this study will continue with the normal standard of care as provided by their personal physician. National registers of cancer, hospital contacts, and socio-economic factors will be the sole data source.

According to Danish, Finnish, Norwegian, and Swedish law register-based studies can be carried out without consent from the data subjects where the processing takes place for the sole purpose of carrying out statistical or scientific studies of significant public importance and where such processing is necessary in order to carry out these studies. It is an absolute requirement that the publication of statistical or scientific results may never reveal the identity of individuals or otherwise compromise data subjects. We will obtain approval by the data agencies in the four countries before data management and data analyses will be performed.

11. Management and reporting of adverse events/adverse reactions

11.1. Definition of Adverse Event

An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product or who undergoes a protocol-specified procedure and which does not necessarily have to have a causal relationship with this treatment or procedure. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal l product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor’s product, is also an adverse event.

Changes resulting from normal growth and development that do not vary significantly in frequency or severity from expected levels are not to be considered adverse events. Examples of this may include, but are not limited to, teething, typical crying in infants and children and onset of menses or menopause occurring at a physiologically appropriate time.

Sponsor's product includes any pharmaceutical product, biological product, device, diagnostic agent or protocol-specified procedure, whether investigational (including placebo or active comparator product) or marketed, manufactured by, licensed by, provided by or distributed by the Sponsor for human use.

Adverse events may occur during the course of the use of the Sponsor's product in studies or within the follow-up period specified by the protocol, or prescribed in clinical practice, from overdose (whether accidental or intentional), from abuse and from withdrawal.

11.2. Definition of Serious Adverse Event

"Serious Adverse Event" (SAE) means an adverse event which is fatal or life threatening, results in persistent or significant disability/incapacity, requires inpatient hospitalization, prolongation of existing inpatient hospitalization, or is a congenital anomaly/birth defect, cancer, the result of an overdose or is another important medical event. Other important medical events that may not result in death, may not be life-threatening, or may not require hospitalization may be considered a Serious Adverse Event when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the other outcomes listed previously. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home and blood dyscrasias or convulsions that do not result in inpatient hospitalization.

11.3. Adverse Event Reporting

If, through the conduct of this study, an investigator (or other study personnel) becomes aware of any serious adverse experience that is possibly, probably, or definitely related to an investigational or marketed product manufactured by Merck & Co., Inc., Schering Corporation, or MSP Singapore LLC, it should be reported to one of the persons on the sponsor contact information list within 24 hours of identification. The end of study report, and any interim analysis, will include aggregate listings of all SAEs and any non-serious AEs collected for and protocol-specified procedures, and will be provided to regulatory agencies as required by the Sponsor.

12. Plans for disseminating and communicating study results

The project will be published in a study report encompassing in detail the data sources, data management, analyses, and results. The outcomes will also be published in international peer reviewed journals if possible. The aim is to get publications in a well-perceived journal focusing on the area of research.

13. References

1. Bird ST, Brophy JM, Hartzema AG, Delaney JAC, Etminan M. Male breast cancer and 5alpha-reductase inhibitors finasteride and dutasteride. J Urol 2013;190:1811-1814.
2. Brinton LA, Cook MB, McCormack V, et al. Anthropomorphic and hormonal risk factors for male breast cancer: Male Breast Cancer Pooling Project results. J Natl Cancer Instit 2014 (*in press*).
3. Christensen AI, Ekholm O, Davisen M, Juel K. Sundhed og sygelighed i Danmark 2010 - og udviklingen siden 1987. Statens Institut for Folkesundhed, Syddansk Universitet. 2012.

4. Dupont WD (1988). Power calculations for matched case-control studies. Biometrics, 44, 1157-1168
5. Engholm G, Ferlay J, Christensen N, Johannesen TB, Klint Å, Køtlum JE, Milter MC, Ólafsdóttir E, Pukkala E, Storm HH. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 5.1 (March 2012). Association of the Nordic Cancer Registries. Danish Cancer Society. Available from http://www.ancr.nu [Accessed on 16/10/2012].
6. Gissler M, Haukka J. Finnish health and social welfare registers in epidemiological research. NorskEpidemiologi 2004;14:113-120.
7. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011;39:42-45.
8. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999;10:37-48.
9. Helakorpi S, Prättälä R, Uutela A. Health Behaviour and Health among the Finnish Adult Population, Spring 2007. Publications of the National Public Health Institute, B6 /2008, KTL-National Public Health Institute, Finland Department of Health Promotion and Chronic Disease Prevention Health Promotion Unit, Helsinki 2008.
10. Jensen AR, Overgaard J, Storm HH. Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark. Eur J Cancer Prev 2002;11:359-364.
11. Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, Dickinson BD. Male breast cancer: risk factors, diagnosis, and management (review). Oncol Rep 2010;24:1115-1120.
12. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;39:38-41.
13. Lee SC, Ellis RJ. Male breast cancer during finasteride therapy. J Natl Cancer Inst 2004;96:338-339.
14. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39:30-33.
15. MHRA. The risk of male breast cancer with finasteride. MHRA Public Assessment Report 2009.
16. Pedersen CB, Gøtzsche H, Møller JØ, Mortensen PB. The Danish civil registration system – a cohort of eight million persons. Dan Med Bull 2006;53:441-449.
17. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011;39:22-25.
18. Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. Scand J Public Health 2011;39:95-98.
19. Pukkala E, Martinsen JI, Lynge E, Gunnarsdottir HK, Sparen P, Tryggvadottir L, Weiderpass E, Kjaerheim K. Occupation and cancer – follow-up of 15 million people in five Nordic countries. Acta Oncol 2009;48:646-79.
20. Pukkala E. Biobanks and Registers in Epidemiologic Research on Cancer. In: Dillner J (ed). Methods in Biobanking, Methods in Molecular Biology Book Series No. 675, The Humana Press, Springer 2011.
21. Rothman KJ.Measuring disease occurrence and casual effects. In: Rothman KJ. Epidemiology: An Introduction. New York: Oxford University Press Inc. 2002; 24–56.

22. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology (3rd ed.). Philadelphia: Lippincott Williams & Wilkins 2008.
23. Shenoy NK, Prabhakar SM. Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link? J Cutan Aesthet Surg 2010;3:102-105.
24. Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: Structure, access, legislation, and archiving. Scand J Public Health 2011;39:12-16.
25. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Männistö S, Sundvall J, Jousilahti P, Salomaa V, Valsta L, Puska P. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010;8:63-71.

Annex 1. List of stand-alone documents

Document	Document number
Stage 1 Research protocol: A multinational, observational registry-based study on a potential link between finasteride and male breast cancer in 4 Nordic countries	1
Stage 1 Study report: A multinational, observational register-based study on a potential link between Finasteride and male breast cancer in four Nordic countries	2
Study Timeline	3
Statistical Analysis Plan	4

Annex 2. ENCePP checklist for study protocols

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance

Doc.Ref. EMA/540136/2009

ENCePP Checklist for Study Protocols (Revision 2, amended)

Adopted by the ENCePP Steering Group on 14/01/2013

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) welcomes innovative designs and new methods of research. This Checklist has been developed by ENCePP to stimulate consideration of important principles when designing and writing a pharmacoepidemiological or pharmacovigilance study protocol. The Checklist is intended to promote the quality of such studies, not their uniformity. The user is also referred to the ENCePP Guide on Methodological Standards in Pharmacoepidemiology which reviews and gives direct electronic access to guidance for research in pharmacoepidemiology and pharmacovigilance.

For each question of the Checklist, the investigator should indicate whether or not it has been addressed in the study protocol. If the answer is "Yes", the page number(s) of the protocol where this issue has been discussed should be specified. It is possible that some questions do not apply to a particular study (for example in the case of an innovative study design). In this case, the answer 'N/A' (Not Applicable) can be checked and the "Comments" field included for each section should be used to explain why. The "Comments" field can also be used to elaborate on a "No" answer.

This Checklist should be included as an Annex by marketing authorisation holders when submitting the protocol of a non-interventional post-authorisation safety study (PASS) to a regulatory authority (see the Guidance on the format and content of the protocol of non-interventional post-authorisation safety studies). Note, the Checklist is a supporting document and does not replace the format of the protocol for PASS as recommended in the Guidance and Module VIII of the Good pharmacovigilance practices (GVP).

Study title:
Finasteride and male breast cancer – a register-based nested case-control study in Denmark, Finland, Norway, and Sweden

Study reference number:
not registered on EU PAS; registered on Clinical Trials NCT01703520

Section 1: Milestones	**Yes**	**No**	**N/A**	**Page Number(s)**
1.1 Does the protocol specify timelines for				
1.1.1 Start of data collection[1]	☒	☐	☐	Annex 1
1.1.2 End of data collection[2]	☒	☐	☐	Annex 1
1.1.3 Study progress report(s)	☐	☒	☐	
1.1.4 Interim progress report(s)	☐	☒	☐	
1.1.5 Registration in the EU PAS register	☐	☐	☒	
1.1.6 Final report of study results.	☒	☐	☐	Annex 1

Comments:
There will be a final report one year after study start.

[1] Date from which information on the first study is first recorded in the study dataset or, in the case of secondary use of data, the date from which data extraction starts.
[2] Date from which the analytical dataset is completely available.

Section 2: Research question	**Yes**	**No**	**N/A**	**Page Number(s)**
2.1 Does the formulation of the research question and objectives clearly explain:				
2.1.1 Why the study is conducted? (e.g. to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)	☒	☐	☐	3,6
2.1.2 The objective(s) of the study?	☒	☐	☐	3,6
2.1.3 The target population? (i.e. population or subgroup to whom the study results are intended to be generalised)	☒	☐	☐	3,7-9
2.1.4 Which formal hypothesis(-es) is (are) to be tested?	☒	☐	☐	6
2.1.5 If applicable, that there is no *a priori* hypothesis?	☐	☐	☒	

Comments:

Section 3: Study design	**Yes**	**No**	**N/A**	**Page Number(s)**
3.1 Is the study design described? (e.g. cohort, case-control, randomised controlled trial, new or alternative design)	☒	☐	☐	7-8
3.2 Does the protocol specify the primary and secondary (if applicable) endpoint(s) to be investigated?	☒	☐	☐	10
3.3 Does the protocol describe the measure(s) of effect? (e.g. relative risk, odds ratio, deaths per 1000 person-years, absolute risk, excess risk, incidence rate ratio, hazard ratio, number needed to harm (NNH) per year)	☒	☐	☐	10

Comments:

Section 4: Source and study populations	**Yes**	**No**	**N/A**	**Page Number(s)**
4.1 Is the source population described?	☒	☐	☐	7-8
4.2 Is the planned study population defined in terms of:				
4.2.1 Study time period?	☒	☐	☐	7-8
4.2.2 Age and sex?	☒	☐	☐	7-8
4.2.3 Country of origin?	☒	☐	☐	7-8
4.2.4 Disease/indication?	☒	☐	☐	7-8
4.2.5 Co-morbidity?	☒	☐	☐	7-8
4.2.6 Seasonality?	☐	☐	☒	
4.3 Does the protocol define how the study population will be sampled from the source population? (e.g. event or inclusion/exclusion criteria)	☒	☐	☐	7-8

Comments:

In addition to the protocol, there is a stand-alone statistical analysis plan that details this.

Section 5: Exposure definition and measurement	**Yes**	**No**	**N/A**	**Page Number(s)**
5.1 Does the protocol describe how exposure is defined and measured? (e.g. operational details for defining and categorising exposure)	☒	☐	☐	10
5.2 Does the protocol discuss the validity of exposure measurement? (e.g. precision, accuracy, prospective				

Section 5: Exposure definition and measurement	Yes	No	N/A	Page Number(s)
ascertainment, exposure information recorded before the outcome occurred, use of validation sub-study)	☒	☐	☐	10, 22
5.3 Is exposure classified according to time windows? (e.g. current user, former user, non-use)	☒	☐	☐	10
5.4 Is exposure classified based on biological mechanism of action and taking into account the pharmacokinetics and pharmacodynamics of the drug?	☒	☐	☐	10
5.5 Does the protocol specify whether a dose-dependent or duration-dependent response is measured?	☒	☐	☐	21-22

Comments:

In addition to the protocol, there is a stand-alone statistical analysis plan that details this.

Section 6: Endpoint definition and measurement	Yes	No	N/A	Page Number(s)
6.1 Does the protocol describe how the endpoints are defined and measured?	☒	☐	☐	10
6.2 Does the protocol discuss the validity of endpoint measurement? (e.g. precision, accuracy, sensitivity, specificity, positive predictive value, prospective or retrospective ascertainment, use of validation sub-study)	☒	☐	☐	10

Comments:

In addition to the protocol, there is a stand-alone statistical analysis plan that details this.

Section 7: Confounders and effect modifiers	Yes	No	N/A	Page Number(s)
7.1 Does the protocol address known confounders? (e.g. collection of data on known confounders, methods of controlling for known confounders)	☒	☐	☐	10-16
7.2 Does the protocol address known effect modifiers? (e.g. collection of data on known effect modifiers, anticipated direction of effect)	☐	☒	☐	

Comments:

As per the protocol, there will be no investigation of effect modifiers of the main association study.

Section 8: Data sources	Yes	No	N/A	Page Number(s)
8.1 Does the protocol describe the data source(s) used in the study for the ascertainment of:				
8.1.1 Exposure? (e.g. pharmacy dispensing, general practice prescribing, claims data, self-report, face-to-face interview, etc.)	☒	☐	☐	10-17
8.1.2 Endpoints? (e.g. clinical records, laboratory markers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics, etc.)	☒	☐	☐	10-17
8.1.3 Covariates?	☒	☐	☐	10-17
8.2 Does the protocol describe the information available from the data source(s) on:				
8.2.1 Exposure? (e.g. date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber)	☒	☐	☐	10-17
8.2.2 Endpoints? (e.g. date of occurrence, multiple event, severity measures related to event)	☒	☐	☐	10-17
8.2.3 Covariates? (e.g. age, sex, clinical and drug use history, co-morbidity, co-medications, life style, etc.)	☒	☐	☐	10-17

Section 8: Data sources	**Yes**	**No**	**N/A**	**Page Number(s)**
8.3 Is a coding system described for:				
8.3.1 Diseases? (e.g. International Classification of Diseases (ICD)-10)	☒	☐	☐	10-17
8.3.2 Endpoints? (e.g. Medical Dictionary for Regulatory Activities (MedDRA) for adverse events)	☒	☐	☐	10-17
8.3.3 Exposure? (e.g. WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC)Classification System)	☒	☐	☐	10-17
8.4 Is the linkage method between data sources described? (e.g. based on a unique identifier or other)	☒	☐	☐	10-17

Comments:

In addition to the protocol, there is a stand-alone statistical analysis plan that details this.

Section 9: Study size and power	**Yes**	**No**	**N/A**	**Page Number(s)**
9.1 Is sample size and/or statistical power calculated?	☒	☐	☐	17-20

Comments:

In addition to the protocol, there is a stand-alone statistical analysis plan that details this.

Section 10: Analysis plan	**Yes**	**No**	**N/A**	**Page Number(s)**
10.1 Does the plan include measurement of excess risks?	☒	☐	☐	21-22
10.2 Is the choice of statistical techniques described?	☒	☐	☐	21-22
10.3 Are descriptive analyses included?	☒	☐	☐	21-22
10.4 Are stratified analyses included?	☒	☐	☐	21-22
10.5 Does the plan describe methods for adjusting for confounding?	☒	☐	☐	21-22
10.6 Does the plan describe methods addressing effect modification?	☐	☒	☐	

Comments:

In addition to the protocol, there is a stand-alone statistical analysis plan that details this.

Section 11: Data management and quality control	**Yes**	**No**	**N/A**	**Page Number(s)**
11.1 Is information provided on the management of missing data?	☒	☐	☐	20,22
11.2 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)	☒	☐	☐	20
11.3 Are methods of quality assurance described?	☒	☐	☐	22
11.4 Does the protocol describe possible quality issues related to the data source(s)?	☒	☐	☐	22
11.5 Is there a system in place for independent review of study results?	☒	☐	☐	22

Comments:

In addition to the protocol, there is a stand-alone statistical analysis plan that details the handling of missing data.

Section 12: Limitations	Yes	No	N/A	Page Number(s)
12.1 Does the protocol discuss:				
12.1.1 Selection biases?	☒	☐	☐	23
12.1.2 Information biases? (e.g. anticipated direction and magnitude of such biases, validation sub-study, use of validation and external data, analytical methods)	☒	☐	☐	22-23
12.2 Does the protocol discuss study feasibility? (e.g. sample size, anticipated exposure, duration of follow-up in a cohort study, patient recruitment)	☒	☐	☐	18-19
12.3 Does the protocol address other limitations?	☒	☐	☐	23

Comments:

In addition to the protocol, there is a stand-alone statistical analysis plan that details this.

Section 13: Ethical issues	Yes	No	N/A	Page Number(s)
13.1 Have requirements of Ethics Committee/Institutional Review Board approval been described?	☒	☐	☐	23-24
13.2 Has any outcome of an ethical review procedure been addressed?	☒	☐	☐	23-24
13.3 Have data protection requirements been described?	☒	☐	☐	23-24

Comments:

Section 14: Amendments and deviations	Yes	No	N/A	Page Number(s)
14.1 Does the protocol include a section to document future amendments and deviations?	☒	☐	☐	5

Comments:

Section 15: Plans for communication of study results	Yes	No	N/A	Page Number(s)
15.1 Are plans described for communicating study results (e.g. to regulatory authorities)?	☒	☐	☐	25
15.2 Are plans described for disseminating study results externally, including publication?	☒	☐	☐	25

Comments:

In addition, this study has an external Scientific review committee that independantly reviews all study results and reports.

Name of the main author of the protocol: PPD

Date: 16 / 1 / 20

Signature: PPD

Annex 3. Products Reference Numbers

Propecia

Member State Initials	Name of MAH	Name of Product	National Authorisation Number(s)	MR procedure number (if applicable)	Pharmaceutical form(s)	Strength(s)
AT	Merck Sharp & Dohme Ges.m.b.H	Propecia 1 mg Filmtabletten	1-24532	SE/H/0158/001	Film Coated Tablet	1 mg
CY	Merck Sharp & Dohme B.V., The Netherlands	PROPECIA	18318	N/A	Film-coated tablets	1 mg
CZ	Merck Sharp & Dohme B.V.	Propecia	87/244/99-C	N/A	Film-coated tablets	1 mg
DE	MSD SHARP & DOHME GMBH Lindenplatz 1 85540 Haar	Propecia 1 mg Filmtabletten	44270.00.00	SE/H/0158/001	Film Coated Tablets	1 mg
DK	Merck Sharp & Dohme B.V., The Netherlands	Propecia	30252	SE/H/0158/001	Film-coated tablets	1 mg
EE	Merck Sharp & Dohme OÜ	Propecia	238498	N/A	Film-coated tablet	1 mg
EL	Vianex S.A.	PROPECIA	74574/25-10-2012	SE/H/0158/001	Film-coated tablet	1 mg
ES	Merck Sharp & Dohme de España, S.A.	Propecia 1 mg comprimidos recubiertos con película	62.441	SE/H/0158/001	Film-coated tablet	1 mg
FI	Merck Sharp & Dohme B.V., The Netherlands	Propecia	13713	SE/H/0158/001	Film-coated tablets	1 mg
FR	MSD France	Propecia 1mg comprimé pelliculé	34009 349 065 4 1, 34009 349 066 0 2 34009 349 067 7 0 34009 349 068 3 1 34009 349 070 8 1	SE/H/0158/001	Film-coated tablets	1 mg
HR	Merck Sharp & Dohme d.o.o.	PROPECIA 1 mg filmom	UP/I-530-09/09-02/408	N/A	Film-coated tablets	1 mg

Proscar

PRODUCT: Proscar				
PSUR period: 19-Aug-12 to 18-Aug-13				
EU Member State	**Local Product Name**	**Pharmaceutical Form**	**Strength**	**Authorisation number**
Austria	Proscar 5 mg Tabletten	Film-coated tablets	5 mg	1-19689
Belgium	Proscar	Film-coated tablet	5 mg	922 IS 151 F3
Bulgaria	Proscar	Film-coated tablet	5mg	20011070
Croatia	Proscar 5 mg filmom obložene tablete	Film-coated tablet	5mg	UP/I-530-09/09-02/409
Cyprus	Proscar	Film-coated tablet	5mg	19539
Czech	Not registered	N/A	N/A	N/A
Denmark	Proscar	Film-coated tablet	5 mg	14514
Estonia	Not registered	N/A	N/A	N/A
Finland	Proscar	Film-coated tablet	5 mg	10751
France	Chibro-Proscar, comprimé pelliculé	Film-coated tablet	5 mg	3400933524845 (28 tablets PVC/Aluminum) 3400933524906 (28 tablets Aluminium/Aluminum) 3400933568849 (14 tablets PVC/Aluminum) 3400933568900 (14 tablets Aluminium/Aluminum) 3400933569150 (5 tablets Aluminium/Aluminum) 3400933569099 (5 tablets PVC/Aluminum) 3400937909075 (84 tablets PVC/Aluminum) 3400937909136 (90 tablets PVC/Aluminum)
Germany	Proscar 5 mg Filmtabletten	Filmcoated tablets	5 mg	42859.00.00
Greece	Proscar	FC tab	5 mg	55487/9-8-2010
Hungary	Proscar	Film-coated tablets	5 mg	OGYI-T-2186/01
Iceland	Not registered	N/A	N/A	
Ireland	Proscar 5mg Film Coated Tablet	Film coated tablets	5 mg	1286/17/1

Proscar, continued

PRODUCT: Proscar				
PSUR period: 19-Aug-12 to 18-Aug-13				
EU Member State	**Local Product Name**	**Pharmaceutical Form**	**Strength**	**Authorisation number**
Italy	Proscar 5 mg compresse rivestite con film	Film-coated tablets	5 mg	028308017 (15 tablets) 028308029 (30 tablets)
Latvia	Not registered	N/A	N/A	N/A
Liechtenstein	National via Switzerland , Proscar,	Film coated tablets	5 mg	51'774
Lithuania	Not registered	N/A	N/A	N/A
Luxembourg	Proscar	Film-coated tablet	5 mg	0483/03107721
Malta	Proscar	Film-coated tablet	5 mg	MA058/00701
Netherlands	Proscar	Film-coated tablet	5 mg	RVG 15482
Norway	Proscar	Tablets	5 mg	7841
Poland	PROSCAR	Film-coated tablets	5 mg	R/3621
Portugal	PROSCAR	Film-coated tablets	5 mg	2133189 (14) 2133288 (28) 2133387 (56)
	FINASTERIDA FROSST	Film-coated tablets	5 mg	2327484 (14) 2327583 (28) 2327682 (56)
Romania	PROSCAR	Film-coated tablets	5 mg	6268/2006/01-02
Slovakia	Not registered	N/A	N/A	N/A
Slovenia	PROSTIDE 5mg filmsko oblozene tablete	Film coated tablet	5 mg	5363-I-585/08
Spain	Proscar 5mg comprimidos con cubierta pelicular	Film coated tablet	5 mg	59.830
Sweden	Proscar	Filmcoated tablet	5 mg	11644/1991-0107
UK	Proscar 5mg film-coated TABLETS	Film-coated tablet	5 mg	PI 00025/0279

Annex 4. Overview of the data analysis
Substudy 1

Variable	Specification	Types of analysis													
		A	B	C	D	1	2	3	4	5	6	7	8	9	10
Period	Long follow-up (1994/1995-2013)	X	X												
	All periods available: Start: DK (1995), F (1994), N (2008) and S (July 2005) and end: 2013			X	X										
Country	Denmark and Finland	X	X	X	X										
	Norway and Sweden			X	X										
Dependent variable	Finasteride use versus non-use	X		X											
	Cumulative finasteride use		X		X										
Age	Age-stratified					X									
Cohort definition	Benign prostatic hyperplasia cohort						X								
	Compared to users of alpha-blockers							X							
Dependent variable	Years of use								X						
	Years since first use									X					
	Only including 5 mg finasteride										X				
	Change requirement for new users											X			
Surveillance bias	Stratified by variables associated with surveillance bias (Table 3 in protocol)												X		
Latency	Latency analyses													X	
Life-style factors	Analysis of self-reported life-style factors (substudy 1A)														X

Abbreviations: DK, Denmark; F, Finland; N, Norway; S, Sweden; ARI, 5alpha-reductase inhibitor. The letters and numbers of types of analyses refer to the analyses described in section 9.7.

Substudy 2

Variable	Specification	Types of analysis															
		A	B	C	D		1	2	3	4	5	6	7	8	9	10	11
Period	Long follow-up (1994/1995-2013)	X	X														
	All periods available: Start: DK (1995), F (1994), N (2008) and S (July 2005) and end: 2013			X	X												
Country	Denmark and Finland	X	X	X	X												
	Norway and Sweden			X	X												
Exposure	Finasteride use versus non-use	X		X													
	Cumulative finasteride use		X		X												
Age	Age-stratified						X										
Cohort definition	Benign prostatic hyperplasia cohort							X									
	Compared to users of alpha-blockers								X								
Exposure	Finasteride or dutasteride use (i.e. use of any ARI)									X							
	Years of use										X						
	Years since first use											X					
	Only including 5 mg finasteride												X				
	Persons with one prescription as exposed													X			
	Change requirement for new users														X		
Surveillance bias	Stratified by variables associated with surveillance bias (Table 3 in protocol)															X	
Latency	Latency analyses																X

Abbreviations: DK, Denmark; F, Finland; N, Norway; S, Sweden; ARI, 5alpha-reductase inhibitor. The letters and numbers of types of analyses refer to the analyses described in section 9.7.

Annex 5. QUALIFIED PERSON FOR PHARMACOVIGILANCE (QPPV)

ANNEX 5. QUALIFIED PERSON FOR PHARMACOVIGILANCE (QPPV)

PPD
EU Qualified Person for
Risk Management & Pharmacovigilance
PPD

PPD
Deputy Qualfied Person for
Phamacovigilance & Director, EU QPPV office
PPD

Emergency/Out of Hours: GSM numbers above or via PPD

MERCK SHARP & DOHME

Hertford Road
Hoddesdon
Hertfordshire EN11 9BU
Telephone PPD

10 February 2015[2]

Dear Sir/Madam

Re: EU QPPV Signature Page for PASS

INN: Finasteride

Product: MK-0906 – Proscar® and Propecia®

Protocol.: Finasteride and male breast cancer – a register-based nested case-control study in Denmark, Finland, Norway, and Sweden Protocol version identifier: Version 162.01

Epidemiology No.: EP020003.021

Protocol date: 10 November 2014

MAH: Merck Sharp & Dohme BV - Haarlem, NL

In line with the Guideline on Good PharmacoVigilance Practice (GVP), Module VIII – Post-Authorisation Safety Studies (PASS) and according to MSD internal SOPs, this study has been reviewed and approved by the European Qualified Person for Pharmacovigilance.

PPD

Yours faithfully

PPD

EU Qualified Person
For Risk Management & Pharmacovigilance